Clinical trials: completed, in Georgia
Atopic Dermatitis, Eczema
Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with erythema, scaly and oozing plaques, and severe pruritus which has an important impact on quality of life and quality of sleep.
- Trial name
- NCT06930365
- Testing
- Anti-itching and repairing treatment. Emollient., Emollient cream
- Where
- Georgia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- NAOS Les Laboratoires
Seasonal Influenza
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age
The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase…
- Trial name
- NCT06602024
- Testing
- mRNA-1010, Fluarix®, Influsplit® Tetra
- Where
- 301 sites in United States, Belgium and 9 more
- Volunteers
- 40,805 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Hepatitis C, Diagnostic Self Evaluation
HCV Self-testing in Georgia
Self-testing with easy-to-use rapid diagnostic tests has been successfully used for diseases such as HIV. The availability of self-testing has been shown to increase testing rates and testing acceptability in diverse populations…
- Trial name
- NCT04961723
- Testing
- (OraQuick® HCV Self-Test
- Where
- 6 sites in Georgia
- Volunteers
- 1,250 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Influenza, Human
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
This Phase 3 study is a randomized, observer-blind study of MF59-adjuvanted influenza vaccine (aQIV or aTIV) compared with a non-adjuvanted influenza vaccine (QIV or TIV) in adults ≥65 years of age.
- Trial name
- NCT06087640
- Testing
- aQIV or aTIV, QIV or TIV
- Where
- 255 sites in United States, Australia and 19 more
- Volunteers
- 38,769 people, healthy volunteers welcome
- Sponsor
- Seqirus
C3 Glomerulopathy, IgA Nephropathy
Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease
The purpose of AROC3-1001 is to evaluate the safety, tolerability, pharmacokinetics and/or pharmacodynamics in adult healthy volunteers (HVs) and in adult patients with complement-mediated renal disease (C3 Glomerulopathy [C3G]…
- Trial name
- NCT05083364
- Testing
- ARO-C3
- Where
- 16 sites in Australia, Georgia and 5 more
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Covid19, Symptoms and Signs
COVID-19 And Lingering Symptoms In Primary Care Patients
The ongoing corona virus disease 2019 (COVID-19) is a viral acute respiratory tract infection caused by server acute respiratory syndrom coronavirus typ 2 (SARS-CoV-2).
- Trial name
- CALIP (NCT04813731)
- Where
- 13 sites in Belgium, Denmark and 9 more
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Katarina Hedin
Hemophilia a, Hemophilia B
The Safety and Tolerability of SerpinPC in Healthy Men and in Men with Severe Blood Disorders (haemophilia a and B)
The purpose of this study is to investigate the safety and activity in the body of a new drug called SerpinPC. The study will be split into 7 parts: Part 1a will be conducted in healthy male volunteers in the UK (up to 15) and…
- Trial name
- NCT04073498
- Testing
- SerpinPC
- Where
- 3 sites in Georgia, Moldova and 1 more
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- ApcinteX Ltd
Healthy, Hepatitis, Chronic
A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)
The purpose of this study is to evaluate pharmacokinetics and safety data including serious and other adverse events, physical examinations, vital signs, 12-lead electrocardiograms (ECGs) and clinical laboratory results…
- Trial name
- NCT02662712
- Testing
- JNJ-56136379
- Where
- 27 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Janssen Sciences Ireland UC
Vaginal Atrophy
Clinical Performance and Safety of the VITA AV Clinical System
The primary objective of this clinical investigation is to demonstrate that treatment with the VITA AV clinical system is feasible and to evaluate clinical performance and safety when used to improve the symptoms and signs of…
- Trial name
- NCT06207227
- Testing
- VITA AV Clinical System
- Where
- Georgia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AVeta Medical
Ulcerative Colitis
A Clinical Trial to Assess the Safety of SOR102 in Healthy Participants and Patients With Ulcerative Colitis
SOR102-101 is a Phase 1, 3-part, randomised, double-blind, placebo-controlled, FIH study to determine the safety, tolerability, and PK of single, ascending oral doses (SAD) of SOR102 (Part 1) and multiple oral doses (Part 2) of…
- Trial name
- NCT06080048
- Testing
- SOR102
- Where
- 2 sites in Georgia, Ukraine
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Sorriso Pharmaceuticals, Inc.
Safety
Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents
To evaluate the safety, compliance, and pharmacokinetics profile of estetrol monohydrate (E4) 15 mg combined with drospirenone (DRSP) 3 mg in post-menarchal participants between the age of 12 and 17 years + 2 months.
- Trial name
- NCT04792385
- Testing
- E4/DRSP 15/3 mg combined tablet
- Where
- 23 sites in Estonia, Finland and 4 more
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- Estetra
Coronary Artery Disease
Cardiovascular Systems Inc. (CSI) pVAD First in Human Study
This study will collect initial clinical data on the CSI pVAD system to inform device design and finalization.
- Trial name
- NCT05315544
- Testing
- CSI pVAD system
- Where
- Georgia
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Abbott Medical Devices
Smoking
Smoke-free Air Coalitions in Georgia and Armenia
This is a matched-pairs community randomized controlled trial (CRCT) to examine the impact of coalitions promoting smoke-free air policies on individual secondhand smoke exposure (SHSe).
- Trial name
- NCT03447912
- Testing
- Intervention Condition
- Where
- 2 sites in Armenia, Georgia
- Volunteers
- 2,924 people, healthy volunteers welcome
- Sponsor
- Emory University
OAG - Open-Angle Glaucoma
Evaluation of the Compatibility of Different Eye Lid Retractors to the Direct Selective Laser Trabeculoplasty (DSLT) Procedure
Direct Selective Laser Trabeculoplasty (DSLT) is an emerging therapeutic technology to treat glaucoma. DSLT was previously tested in 2 clinical trials and demonstrated promising safety and efficacy results in reducing the…
- Trial name
- NCT05271734
- Testing
- Lid retractor placement
- Where
- Georgia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BelkinVision
Eczema Eyelid
Ocular, Periocular and Cutaneous Tolerance and Efficacy of Formula 2039002 10 in Patients With Palpebral Eczema
The eyelids are particularly susceptible to eczema. Eyelid eczemas also called palpebral eczema, are a common condition that causes the skin on or around the eyelid to become dry, itchy, and irritated.
- Trial name
- NCT05540496
- Where
- 2 sites in Georgia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Hepatitis C
Truenat™ HCV RNA Assay Evaluation
Molbio Diagnostics Ltd. (India) has developed the Truelab™ Real Time quantitative PCR system that is widely used in India for diagnostics of tuberculosis (TB).
- Trial name
- NCT04236973
- Testing
- Molbio Truenat™ HCV assay (the investigational product), Abbott RealTime HCV assay
- Where
- 5 sites in Denmark, Ethiopia and 3 more
- Volunteers
- 1,330 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Active Tuberculosis, Latent Tuberculosis Infection
Performance Evaluation of the VIDAS TB-IGRA Assay.
This study will evaluate the performance of the VIDAS® Interferon Gamma (IFN-γ) Release Assay (TB-IGRA) assay, which is intended for use as an aid in the diagnosis of tuberculosis infection.
- Conditions
- Active Tuberculosis, Latent Tuberculosis Infection, Non-Tuberculous Mycobacterial (NTM) Pneumonia
- Trial name
- NCT04048018
- Testing
- Blood draw and IGRA test
- Where
- 24 sites in United States, Brazil and 7 more
- Volunteers
- 2,401 people, healthy volunteers welcome
- Sponsor
- BioMérieux
Ulcerative Colitis
SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101
A randomized, double-blind placebo-controlled first in human study in approximately 36 male healthy subjects and approximately 20 male and female patients with active UC who have had an inadequate response to or demonstrated…
- Trial name
- AURIGA1 (NCT04224857)
- Testing
- AMT-101
- Where
- 4 sites in Georgia, Germany and 2 more
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Applied Molecular Transport
Menopause
Effect of Menopause Relief EP-40 in Women With Menopausal Symptoms
This study compares the efficacy of a fixed combination of black cohosh (EP-40) and Rhodiola rosea (EPR-7) with low (6.5 mg) and high doses (500 mg) of a standardized black cohosh extract only in adult woman with menopausal…
- Trial name
- NCT03461380
- Testing
- Menopause Relief EP-40, Low Dose Black Cohosh, High Dose Black Cohosh
- Where
- Georgia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- EuroPharma, Inc.
Chronic Hepatitis C
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
This randomized, double-blind, placebo-controlled, 3-part study will assess the safety, tolerability, and pharmacokinetics of orally administered AL-335 in healthy volunteers (HV) and subjects with CHC infection.
- Trial name
- NCT02339207
- Testing
- AL-335
- Where
- 3 sites in France, Georgia and 1 more
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.